Dr Martin Moore | Associate Professor, Interim Director of Research, Pediatric Infectious Diseases
Emory University Children’s Center | United States

Dr Martin Moore, Associate Professor, Interim Director of Research, Pediatric Infectious Diseases, Emory University Children’s Center

Dr. Martin Moore received his PhD in Genetics from the University of Georgia in 2002, studying adenovirus. He was a postdoctoral fellow in the laboratory of Dr. Stokes Peebles at Vanderbilt from 2004 to 2008, investigating RSV strains and pathogenesis. In 2008, Marty joined the faculty of Pediatric Infectious Disease at Emory University, where his group developed mouse models of RSV infection and a plasmid-based RSV genetic system. In 2016, Marty received tenure and was named Director of the Emory and Children’s Healthcare of Atlanta Center for Childhood Infections and Vaccines and Interim Director of Research of the Division of Pediatric Infectious Diseases at Emory. Marty is also Co-Founder and C.E.O of Meissa Vaccines, Inc, a full-time role while on leave from academics. 
Dr. Martin Moore received his PhD in Genetics from the University of Georgia in 2002, studying adenovirus. He was a postdoctoral fellow in the laboratory of Dr. Stokes Peebles at Vanderbilt from 2004 to 2008, investigating RSV strains and pathogenesis. In 2008, Marty joined the faculty of Pediatric Infectious Disease at Emory University, where his group developed mouse models of RSV infection and a plasmid-based RSV genetic system. In 2016, Marty received tenure and was named Director of the Emory and Children’s Healthcare of Atlanta Center for Childhood Infections and Vaccines and Interim Director of Research of the Division of Pediatric Infectious Diseases at Emory. Marty is also Co-Founder and C.E.O of Meissa Vaccines, Inc, a full-time role while on leave from academics. 

Appearances:



DC Co-conference Day 2 April 4 @ 09:40

Achieving an effective balance of attenuation and immunogenicity for RSV live attenuated vaccines (LAV)

·         Engineering RSV LAV strains with enhanced immunogenicity using a multi-faceted, rational mutagenesis approach

·         Enhancing expression of the pre-fusion conformation of the RSV fusion (F) protein

·         Using genetic mapping to identify residues that correlate with pre-fusion antigen maintenance and thermal stability of infectivity into LAV candidates

·         Candidates exhibiting elevated pre-fusion antigen levels, thermal stability, immunogenicity, and efficacy

back to speakers